Transfection News and Research

RSS

NPH acquires an exclusive license from UCLA for a suite of supramolecular nanoparticle technologies

NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles.

9 Dec 2009

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.

25 Nov 2009

Micro-injector may help rapid development of new generation of drugs

It's no bigger than a stamp packet but it has the potential to allow rapid development of a new generation of drugs and genetic engineering organisms, and to better control in-vitro fertilization.

5 Nov 2009

Sigma-Aldrich, Polyplus-transfection sign licensing agreement to manufacture ZNA oligonucleotides

Sigma-Aldrich today announced a worldwide licensing agreement with Polyplus-transfection (Strasbourg, France) to manufacture and commercialize Zip Nucleic Acid (ZNA(TM)) oligonucleotides, a new technology that provides solutions for increased affinity for nucleic acids.

3 Nov 2009

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

The C-terminal domain (CTD) of RNA Polymerase II consists of multiple repeats of an evolutionary conserved motif of seven amino acids, forming a repetitive structure of 52 repeats in humans and 26 repeats in yeast. Twenty years after the first description of the RNA polymerase II C-terminal domain, its function is still unclear.

23 Oct 2009

Bio-Path Holdings to develop liposome tumor targeting technology

Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).

23 Sep 2009

TransIT-2020 transfection reagent released by Mirus Bio

From the transfection experts, Mirus Bio introduces its next generation transfection reagent, TransIT(R)-2020 Transfection Reagent.

9 Sep 2009

microRNAs manipulate cells to one day create safe embryonic-like stem cells

A team of UCSF researchers has for the first time used tiny molecules called microRNAs to help turn adult mouse cells back to their embryonic state.

12 Apr 2009

Targeted nanoparticles deliver therapeutic DNA to cancer cells

Given that cancer is a disease caused by gene mutations, cancer researchers have been striving to develop gene therapies aimed at correcting these mutations. However, these efforts have been hobbled by the difficulty in safely and efficiently delivering anticancer genes to tumors. Nanoparticles, however, may solve these delivery issues, and two recently published studies, using two different types of nanoparticles, lend credence to that hypothesis.

29 Dec 2008

MaxCyte STX scalable transfection system launched in London

MaxCyte, Inc announced today the European launch of the MaxCyte STX Scalable Transfection System at SMi's Cell-Based Assay Conference held in London, November 19 and 20, 2008.

18 Nov 2008

Roche acquires Mirus to advance RNAi delivery research

Roche (Basel) and Mirus Bio Corporation (Madison, WI, USA) announced today that they have entered into a definitive agreement under which Roche will acquire Mirus Bio Corporation, a privately-owned US company based in Madison, Wisconsin, that focuses on the discovery and development of innovative nucleic acid based technologies, including a proprietary RNAi (Ribonucleic Acid interference) delivery platform.

22 Jul 2008

Most comprehensive kinome collection

Scientists from University of Helsinki, Institute of Molecular Medicine in Finland and OriGene Technologies joined effort in creating the most comprehensive kinome collection of nearly all predicted human protein kinases, including the functional kinases and their kinase-deficient counterparts. Equipped with this collection, the authors successfully identified novel kinase regulators in Hedgehog signaling pathway and in activation of Karposi's Sarcoma herpesvirus.

5 May 2008

MaxCyte introduces large scale transfection technology - accelerates cell-based assay development

MaxCyte has announced the introduction of its ITF Inline Transfection System, a validated platform for preparative transfection, based on unique flow electroporation technology.

21 Apr 2008

Novel approach may lead to safer delivery of genetic therapies

A novel strategy for circumventing safety problems that have plagued gene therapy has been offered by a complex multicenter group of researchers, including Professor Claudio Napoli, a Full Professor at the II University of Naples and Adjunct Professor at the Sbarro Research Institute for Cancer Research and Molecular Medicine and the Center of Biotechnology at the College of Science and Technology of Temple University.

24 Mar 2008

Thermo Fisher Scientific creates breakthrough gene-silencing tool

Thermo Fisher Scientific Inc. has developed a breakthrough gene-silencing tool that greatly simplifies RNA- interference (RNAi) technology and eliminates barriers associated with previous cellular delivery methods.

From Thermo Fisher Scientific Inc. 12 Mar 2008

Newly discovered ERK pathway proteins related to CagA induced disease

Cytotoxin-associated gene A protein (CagA) from type I H.pylori has been proved by epidemiological and experimental studies to be closely associated with the H.pylori induced gastric diseases, especially gastric cancer.

25 Feb 2008

A new source of islet cells

The shortage of islet cells limits the development of islet transplantation. One new approach was reported in the October 21 issue of the World Journal of Gastroenterology because of its great significance in enhancing the output of islet cells.

25 Oct 2007

New insights into retinal growth

Peering at microscopic changes within the retina, scientists in the Department of Ophthalmology at Weill Cornell Medical College in New York City, have discovered a key mechanism driving eye health and eye disease.

12 Sep 2007

Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes

Researchers open the way for improved study of hepatitis C virus by devising a novel virus culture system that allows replication of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus strains in transformed cell lines.

23 Jan 2007

Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery

Though gene therapies hold great promise for treating cancer, it has proven difficult to deliver therapeutic genes efficiently into cancer cells.

18 Dec 2006